Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis

Published:December 24, 2020DOI:



      Alteplase is an approved treatment for acute ischemic stroke. Tenecteplase is a genetically modified form of alteplase, with lower cost and a more favourable pharmacokinetic profile allowing bolus injection. The aim of this study was to compare both drugs in adult patients with acute ischemic stroke undergoing thrombolysis.

      Material and methods

      PubMed and CENTRAL were searched for observational and experimental studies comparing both drugs in the population of interest. Additional studies were sought in clinical trial registries and by means of reference check. The efficacy outcomes of interest were functional status at 3 months, recanalization and early neurological improvement (ENI). The safety outcomes of interest were cerebral haemorrhage (ICH), symptomatic ICH and mortality. The effect measure of interest was the absolute risk difference (ARD). Effect measures for each outcome were pooled across studies using random effect models.


      Eight studies were included, involving 2031 patients. Overall, there were no differences in terms of good or excellent functional outcome (ARR = 0.07 and 0.03 respectively, p > 0.05 for both comparisons) but tenecteplase patients showed higher rates of recanalization (ARD = 0.11, 95% CI [0.01;0.20]) and ENI (ARD = 0.10, 95% CI [0.02;0.17]). There were no differences between groups in terms of ICH (ARD = -0.02, 95% CI [−0.06;0.01]), symptomatic ICH (ARD = 0.00, 95% CI [−0.01;0.02]) or death (ARD = 0.00, 95% CI [−0.03;0.03]).


      Tenecteplase is an alternative to alteplase for stroke thrombolysis, with lower cost and a more favourable pharmacokinetic profile.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Johnson C.O.
        • Nguyen M.
        • Roth G.A.
        • Nichols E.
        • Alam T.
        • Abate D.
        • et al.
        Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
        Lancet Neurol. 2019 May 1; 18 ([Internet]. [cited 2020 Aug 11]. (Available from: doi:10.1016/)): 439-458
        • Powers W.J.
        • Rabinstein A.A.
        • Ackerson T.
        • Adeoye O.M.
        • Bambakidis N.C.
        • Becker K.
        • et al.
        Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association [Internet].
        in: Stroke. Vol. 50. Lippincott Williams and Wilkins, 2019: E344-E418 ([cited 2020 Aug 11]. Available from)
        • Ahmed N.
        • Audebert H.
        • Turc G.
        • Cordonnier C.
        • Christensen H.
        • Sacco S.
        • et al.
        Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11–13 November 2018.
        Eur Stroke J. 2019 Dec 2; 4 ([Internet]. [cited 2020 Aug 11]. Available from:): 307-317
        • Tanswell P.
        • Modi N.
        • Combs D.
        • Danays T.
        Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction [Internet].
        in: Clinical Pharmacokinetics. Vol. 41. Springer, 2002: 1229-1245 ([cited 2020 Aug 11]. Available from:)
        • Campbell B.C.V.
        • Mitchell P.J.
        • Churilov L.
        • Yassi N.
        • Kleinig T.J.
        • Dowling R.J.
        • et al.
        Tenecteplase versus alteplase before thrombectomy for ischemic stroke.
        N Engl J Med. 2018; 378: 1573-1582
        • Burgos A.M.
        • Saver J.L.
        Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials.
        Stroke. 2019 Aug; 50: 2156-2162
        • Wardlaw J.M.
        • Koumellis P.
        • Liu M.
        Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke.
        Cochrane Database Syst Rev. 2013 May; 5CD000514
        • Moher D.
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        Ann Intern Med. 2009 Aug 18; 151 ([Internet]. [cited 2020 Aug 11]. Available from:): 264
        • Parsons M.W.
        • Miteff F.
        • Bateman G.A.
        • Spratt N.
        • Loiselle A.
        • Attia J.
        • et al.
        Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window.
        Neurology. 2009 Mar; 72: 915-921
        • Haley E.C.J.
        • Thompson J.L.P.
        • Grotta J.C.
        • Lyden P.D.
        • Hemmen T.G.
        • Brown D.L.
        • et al.
        Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial.
        Stroke. 2010 Apr; 41: 707-711
        • Parsons M.
        • Spratt N.
        • Bivard A.
        • CAmpbell B.
        • Chung K.
        • Miteff F.
        A randomised trial of tenecteplase versus alteplase for acute ischemic stroke.
        N Engl J Med. 2012; ([Internet]. 366 CC. Available from:): 1099-1107
        • Huang X.
        • Cheripelli B.K.
        • Lloyd S.M.
        • Kalladka D.
        • Moreton F.C.
        • Siddiqui A.
        • et al.
        Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
        Lancet Neurol. 2015 Apr; 14: 368-376
        • Logallo N.
        • Novotny V.
        • Assmus J.
        • Kvistad C.E.
        • Alteheld L.
        • Rønning O.M.
        • et al.
        Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
        Lancet Neurol. 2017; 16: 781-788
        • Rajappa S.
        • SIivakumar S.
        Safety and efficacy of tenecteplase compared to alteplase in acute ischaemic stroke.
        Int J Stroke Confer 11th World Stroke Congr WSC 2018 Canada. 2018; 13 ([Internet]. Available from:): 9-10
        • Seners P.
        • Caroff J.
        • Chausson N.
        • Turc G.
        • Denier C.
        • Piotin M.
        • et al.
        Recanalization before thrombectomy in tenecteplase vs. alteplase-treated drip-and-ship patients.
        J Stroke. 2019; 21: 105-107
        • Rha J.H.
        • Saver J.L.
        The impact of recanalization on ischemic stroke outcome: a meta-analysis.
        Stroke. 2007 Mar 1; 38 ([Internet]. [cited 2020 Aug 18]. Available from:): 967-973
        • Kharitonova T.
        • Mikulik R.
        • Roine R.O.
        • Soinne L.
        • Ahmed N.
        • Wahlgren N.
        • et al.
        Association of early National Institutes of Health Stroke Scale improvement with vessel recanalization and functional outcome after intravenous thrombolysis in ischemic stroke.
        Stroke. 2011 Jun; 42 ([Internet]. [cited 2020 Aug 18]. Available from): 1638-1643
        • Coutts S.B.
        • Dubuc V.
        • Mandzia J.
        • Kenney C.
        • Demchuk A.M.
        • Smith E.E.
        • et al.
        Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
        Stroke. 2015 Mar 1; 46 ([Internet]. [cited 2020 Aug 20]. Available from:): 769-774
        • Haley E.C.
        • Lyden P.D.
        • Johnston K.C.
        • Hemmen T.M.
        A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke.
        Stroke. 2005; 36: 607-612
        • Ramakrishnan T.
        • Kumaravelu S.
        • Narayan S.
        • Buddha S.
        • Murali C.
        • Majeed P.
        • et al.
        Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials..
        Am J Cardiovasc Drugs. 2018; 18: 387-395
        • Campbell B.C.V.
        • Mitchell P.J.
        • Churilov L.
        • Yassi N.
        • Kleinig T.J.
        • Dowling R.J.
        • et al.
        Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial.
        JAMA. 2020; 323: 1257-1265
        • Zitek T.
        • Ataya R.
        • Brea I.
        Using tenecteplase for acute ischemic stroke: what is the hold up?.
        West J Emerg Med. 2020; 21 ([Internet]. [cited 2020 Aug 18]. Available from): 199-202
        • Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis
        Full Text View -
        ([Internet]. [cited 2020 Aug 20]. Available from)
        • Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
        ([Internet]. [cited 2020 Aug 20]. Available from)
        • The Norwegian Tenecteplase Stroke Trial 2 (NOR-TEST 2)
        ([Internet]. [cited 2020 Aug 20]. Available from)
        • Tenecteplase in Wake-up Ischaemic Stroke Trial
        Full Text View -
        ([Internet]. [cited 2020 Aug 20]. Available from)
        • A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
        Full Text View -
        ([Internet]. [cited 2020 Aug 20]. Available from)
        • Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance
        Full Text View -
        ([Internet]. [cited 2020 Aug 20]. Available from)